A Phase I and Pharmacokinetic Study of Temsirolimus (CCI-779) Administered Intravenously Daily for 5 Days Every 2 Weeks to Patients with Advanced Cancer
Manuel Hidalgo et al, 2006, Clinical Cancer Research CrossRef